Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soleno Therapeutics, Inc. - Common Stock (NQ:SLNO)

65.18 -1.72 (-2.57%)
Streaming Delayed Price Updated: 1:42 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Soleno Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet
Via Stocktwits
Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe
Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face market withdrawal. 
Via Benzinga
Soleno (SLNO) Q2 Revenue Jumps 30%
Via The Motley Fool
Soleno Therapeutics Inc (NASDAQ:SLNO) Reports Q2 2025 Earnings Beat with Strong VYKAT™ XR Launch Performance
Soleno Therapeutics (SLNO) reported Q2 2025 revenue of $32.66M, beating estimates by 27.4%, with a narrower EPS loss. Stock rose 1.23% post-earnings amid strong VYKAT™ XR launch. 
Via Chartmill
Topics Earnings
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Soleno Therapeutics's Earnings: A Preview
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress
Aardvark's lead drug ARD-101 targets PWS and HO with trials underway and funding secured through 2027 after a $94.2 million IPO in February. 
Via Benzinga
Topics Initial Public Offering
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Soleno Launches Pill For Hyperphagia In Prader-Willi Syndrome Patients But Retail’s Unmoved
VYKAT XR has now been delivered to the first individuals living with PWS who have been prescribed the medication, the company said. 
Via Stocktwits
Tesla To $455? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
Soleno Shares Are Up Today: What's Going On?
Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA approval for its first commercial drug, Vykat XR (diazoxide choline)... 
Via Benzinga
Top stock movements in today's session.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Which stocks are gapping on Thursday?
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results
 
Via Benzinga
Top movers in Thursday's pre-market session
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher
The drug treats excessive hunger that often leads to obesity in patients with a rare, genetic disease. 
Via Investor's Business Daily
Behind the Scenes of Soleno Therapeutics's Latest Options Trends
 
Via Benzinga
Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks
The company expects the drug, the first approved therapy to address hyperphagia in PWS patients, to be available in the U.S. starting April 2025. 
Via Stocktwits
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder
Soleno's Vykat XR wins FDA approval as the first treatment for hyperphagia in Prader-Willi syndrome, with U.S. availability expected by April 2025. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert
U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading. Aiming... 
Via Benzinga
Topics Supply Chain World Trade
Why Greenland Technologies Shares Are Trading Higher By Around 89%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Why Soleno Therapeutics Stock Blasted 9% Higher Today
The company's Prader-Willi treatment inched closer to FDA approval. 
Via The Motley Fool
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Hain Celestial Posts Upbeat Q4 Earnings, Joins Soleno Therapeutics, Energizer Holdings And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.